AIM ImmunoTech Inc. SEC filings AIM
AIM ImmunoTech Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Dec 6, 2013. Its latest annual report, Form ARS, was filed on Sep 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Nov 3, 2026 | — |
| DEF 14A | Proxy statement | Sep 30, 2026 | Sep 30, 2026 |
| DEF 14A | Proxy statement | Jun 25, 2026 | Jun 25, 2026 |
| PRE 14A | Preliminary proxy statement | Jun 15, 2026 | Jun 15, 2026 |
| DEF 14A | Proxy statement | Oct 29, 2025 | Oct 29, 2025 |
| DEF 14A | Proxy statement | Apr 2, 2025 | Apr 2, 2025 |
| PRE 14A | Preliminary proxy statement | Feb 28, 2025 | Feb 28, 2025 |
| DEFA14A | Additional proxy material | Dec 17, 2024 | — |
| DEFA14A | Additional proxy material | Dec 16, 2024 | — |
| DEFA14A | Additional proxy material | Dec 12, 2024 | — |
| DEFA14A | Additional proxy material | Dec 10, 2024 | — |
| DEFA14A | Additional proxy material | Dec 9, 2024 | — |
| DEFA14A | Additional proxy material | Dec 6, 2024 | — |
| DEFA14A | Additional proxy material | Dec 5, 2024 | — |
| DEFA14A | Additional proxy material | Dec 4, 2024 | — |
| DEFA14A | Additional proxy material | Dec 2, 2024 | — |
| DEFA14A | Additional proxy material | Nov 27, 2024 | — |
| DEFA14A | Additional proxy material | Nov 27, 2024 | — |
| DEFA14A | Additional proxy material | Nov 25, 2024 | — |
| DEFA14A | Additional proxy material | Nov 22, 2024 | — |
| DEFA14A | Additional proxy material | Nov 15, 2024 | — |
| DEFA14A | Additional proxy material | Nov 8, 2024 | — |
| DEFA14A | Additional proxy material | Nov 4, 2024 | — |
| DEFA14A | Additional proxy material | Dec 29, 2023 | — |
| DEFA14A | Additional proxy material | Nov 28, 2023 | — |
| DEFA14A | Additional proxy material | Nov 20, 2023 | — |
| DEFA14A | Additional proxy material | Nov 20, 2023 | — |
| DEFA14A | Additional proxy material | Nov 8, 2023 | — |
| DEFA14A | Additional proxy material | Nov 7, 2023 | — |
| DEFA14A | Additional proxy material | Aug 23, 2023 | — |
| DEFA14A | Additional proxy material | Nov 3, 2022 | — |
| DEFA14A | Additional proxy material | Oct 31, 2022 | — |
| DEFA14A | Additional proxy material | Oct 27, 2022 | — |
| DEFA14A | Additional proxy material | Oct 26, 2022 | — |
| DEFA14A | Additional proxy material | Oct 13, 2022 | — |
| DEFA14A | Additional proxy material | Oct 12, 2022 | — |
| DEFA14A | Additional proxy material | Sep 26, 2022 | — |
| DEFA14A | Additional proxy material | Sep 20, 2022 | — |
| DEFA14A | Additional proxy material | Aug 15, 2022 | — |
| DEF 14A | Proxy statement | Aug 17, 2021 | Aug 17, 2021 |
| DEF 14A | Proxy statement | Aug 11, 2020 | Aug 11, 2020 |
| DEF 14A | Proxy statement | Aug 20, 2019 | Aug 20, 2019 |
| DEF 14A | Proxy statement | Apr 24, 2019 | Apr 24, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 5, 2019 | Apr 5, 2019 |
| DEF 14A | Proxy statement | Aug 3, 2018 | Aug 3, 2018 |
| PRE 14A | Preliminary proxy statement | Jul 19, 2018 | Jul 19, 2018 |
| DEF 14A | Proxy statement | Jul 18, 2017 | Jul 18, 2017 |
| DEFA14A | Additional proxy material | Jul 14, 2016 | — |
| DEF 14A | Proxy statement | Jun 27, 2016 | Jun 27, 2016 |
| PRE 14A | Preliminary proxy statement | Jun 8, 2016 | Jun 8, 2016 |
| DEFA14A | Additional proxy material | May 18, 2016 | — |
| DEFA14A | Additional proxy material | Sep 2, 2015 | — |
| DEFA14A | Additional proxy material | Sep 1, 2015 | — |
| DEFA14A | Additional proxy material | Aug 31, 2015 | — |
| DEFA14A | Additional proxy material | Aug 26, 2015 | — |
| DEFA14A | Additional proxy material | Aug 19, 2015 | — |
| DEF 14A | Proxy statement | Aug 10, 2015 | Aug 10, 2015 |
| PRE 14A | Preliminary proxy statement | Jul 8, 2015 | Jul 8, 2015 |
| DEF 14A | Proxy statement | Jul 7, 2015 | Jul 7, 2015 |
| DEFA14A | Additional proxy material | Oct 29, 2014 | — |
| DEF 14A | Proxy statement | Oct 10, 2014 | Nov 12, 2014 |
Showing 61 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AIM (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ocala, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 946644
- Former names
- AIM ImmunoTech Inc. (until Nov 5, 2026); HEMISPHERX BIOPHARMA INC (until Aug 26, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.